Tilde Sciences, a specialty pharmaceutical company, announced that it has acquired two medicines, Daraprim® and Vecamyl® from Vyera Pharmaceuticals.
Tilde Sciences expects a seamless transition from Vyera Pharmaceuticals and uninterrupted access through Optime Care, its specialty pharmacy partner. Tilde has elected to use Optime Care because of the company's commitment to provide patients and their caregivers with dedicated programs and services in support of these important drugs.